SCH 39641

BIOLOGICAL2 trials

Sponsors

ALK-Abelló A/S

Conditions

AllergyConjunctivitisRhinitisRhinoconjunctivitis

Phase 2

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

CompletedNCT00978029

ALK-Abelló A/SAllergy, Conjunctivitis, Rhinitis +1

Start: 2009-11-30End: 2010-02-28Updated: 2017-03-03

Phase 3

A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

CompletedNCT01469182

ALK-Abelló A/SAllergy

Start: 2011-11-30End: 2012-04-30Updated: 2017-03-03

Related Papers

Safety and tolerability of a short ragweed sublingual immunotherapy tablet.

2014-05-1443 citations